NCT05061537: Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients with known or suspected hypersensitivity to prior treatment with any oncolytic vaccine, pox virus vaccine, or antiviral agents within the past 10 years; Patients with known symptomatic brain metastases requiring steroids

Comments are closed.

Up ↑